HR Execs on the Move

Alkermes

www.alkermes.com

 
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.alkermes.com
  • 852 Winter Street
    Waltham, MA USA 02451
  • Phone: +353 1 772 8000

Executives

Name Title Contact Details
Katie Bizzari
Associate Director, Human Resources Profile
Pete Mello
Executive Director, Talent Aquisition Profile
Eric Brown
Vice President of Sales, Psychiatry Franchise Profile
Daniel Deaver
Vice President Non-Clinical R&D Profile
Joanna Deveau
Senior Director, R&D Integration & Program Management Profile

Similar Companies

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

RoslinCT

RoslinCT is a UK-based Cell and Gene Therapy Contract Development and Manufacturing Organisation (CDMO) that provides services for companies developing cell and gene-based therapeutic products. They offer a range of integrated services from GMP transla...

FDC Vitamins

FDC Vitamins is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bradford Health Services

Its never easy to admit that you or someone you care about is addicted to alcohol or drugs. But once you recognize the problem, the road to recovery appears at your feet. The first step down that road is to find professional help.

MIDi

MIDi is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.